GE Healthcare compensates $30 million to resolve medicare fraud case
The US Justice Department articulated that General Electric Co. (GE)s health-care unit will give in excess of 30 million dollars to resolve claims that a company it bought in 2004 given false information to Medicare to pad billings for a drug used to diagnose heart disease.
The deception settlement declared on Jan. 29 linking the drug Myoview sold by Amersham Health Incorporation resolves claims filed in the False Claims Act. The act permits whistle-blowers to follow fraud claims on behalf of the federal government and then share in any recovery.
post_id:
uld_count:
Cookie not set
Like
Dislike
Value 1: 0
Value 2: 10
